Literature DB >> 25275881

Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy.

Simon Ville1, Jean Philippe Talarmin, Alina Gaultier-Lintia, Régis Bouquié, Christine Sagan, Patrice Le Pape, Magali Giral, Florent Morio.   

Abstract

Three months after a kidney transplant, a man experienced an internuclear ophthalmoplegia. Magnetic resonance imaging found a punctuate hyperintensity of the brainstem. Afterwards, the patient presented with peripheral facial paralysis. A complete morphologic assessment showed an increase of the brainstem lesion, together with an excavated pulmonary nodule. Combination therapy with high-dose liposomal amphotericin B and voriconazole was begun for the putative aspergillosis. Owing to its atypical clinical presentation and negative detection of Aspergillus galactomannan antigen on sera, a biopsy specimen of the lung lesion was obtained. Histopathological and mycological investigations allowed the diagnosis of mucormycosis owing to Rhizopus microsporus. Accordingly, voriconazole was replaced with posaconazole. After 5 months, regression of the cerebral lesion was noted. Disseminated mucormycosis in solid-organ recipients is uncommon and mycological diagnosis is challenging. Mortality is high and is increased by diagnostic delay. Treating mucormycosis requires surgical debridement and appropriate antifungal therapy (usually intravenous liposomal amphotericin B). This report suggests that a combination of liposomal amphotericin B and posaconazole can be a therapeutic option in patients with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25275881     DOI: 10.6002/ect.2014.0093

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  5 in total

Review 1.  Phylogenetic analysis reveals two genotypes of the emerging fungus Mucor indicus, an opportunistic human pathogen in immunocompromised patients.

Authors:  Saad J Taj-Aldeen; Muna Almaslamani; Bart Theelen; Teun Boekhout
Journal:  Emerg Microbes Infect       Date:  2017-07-12       Impact factor: 7.163

Review 2.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 3.  Spectrum of Mucormycosis Before and During COVID-19: Epidemiology, Diagnosis, and Current Therapeutic Interventions.

Authors:  Sheikh Mansoor; Tousief Irshad Ahmed; Karan Happa; Mehnaz Sultan; Sweeta Manhas; Suhaib Shamas
Journal:  Curr Fungal Infect Rep       Date:  2022-08-10

Review 4.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08

5.  Disseminated mucormycosis with cerebellum involvement due to Rhizomucor pusillus in a patient with multiple myeloma and secondary myelodysplastic syndrome: A case report.

Authors:  Qiong Chen; Kuang Chen; Shenxian Qian; Shenghai Wu; Lihui Xu; Xilian Huang; Pengfei Shi; Kaile Wang; Minmin Wang; Xianjun Wang
Journal:  Exp Ther Med       Date:  2019-09-27       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.